A Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
- Male or female patients, >18 years of age, able to understand and give written
- Histologically or cytologically confirmed epithelial adenocarcinoma of one of the
- Breast cancer (BC)
- Colorectal (CRC)
- Gastric adenocarcinoma (GC)
- Hepatocellular carcinoma (HCC)
- Non-small cell lung cancer (NSCLC)
- Ovarian epithelial cancer (OEC)
- Pancreatic ductal adenocarcinoma (PDC)
- Prostate adenocarcinoma (PC) (Note: Confirmation of Trop-2 expression by
immunohistology or other means is not required, but the Sponsor will request tissue
specimens from archived materials for determination of Trop-2 expression.)
- Stage IV (metastatic) disease.
- Previously treated with at least one prior therapeutic regimen, but no more than 3
prior chemotherapy regimens.
- Adequate performance status (ECOG 0 or 1) (Appendix 1)
- Expected survival > 6 months.
- Measurable disease by CT or MRI.
- At least 2 weeks beyond treatment (chemotherapy, immunotherapy and/or radiation
therapy) or major surgery and recovered from all acute toxicities.
- At least 2 weeks beyond corticosteroids (however, low dose corticosteroids < 20 mg
prednisone or equivalent daily are permitted).
- Adequate hematology without ongoing transfusional support (hemoglobin > 9 g/dL, ANC >
2,000 per mm3, platelets > 150,000 per mm3).
- Adequate renal and hepatic function (creatinine ≤ 2.0 x IULN, bilirubin ≤ IULN, AST
and ALT ≤ 3.0 x IULN or 5 x IULN if know liver metastases).
- Otherwise, all toxicity at study entry < Grade 1 by NCI CTC v4.0.
- Women who are pregnant or lactating.
- Women of childbearing potential and fertile men unwilling to use effective
contraception during study until conclusion of 12-week post-treatment evaluation
- Patients with Gilbert's disease.
- Known CNS metastatic disease.
- Presence of bulky disease (defined as any single mass >5 cm in its greatest
- Patients with active ≥ grade 2 anorexia, nausea or vomiting, and/or signs of
- Patients with non-melanoma skin cancer or carcinoma in situ of the cervix are
eligible, while patients with other prior malignancies must have had at least a
3-year disease-free interval.
- Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive.
- Known history of unstable angina, MI, or CHF present within 6 months or clinically
significant cardiac arrhythmia (other than stable atrial fibrillation) requiring
- Known history of clinically significant active COPD, or other moderate-to-severe
chronic respiratory illness present within 6 months.
- Infection requiring intravenous antibiotic use within 1 week.
- Other concurrent medical or psychiatric conditions that, in the Investigator's
opinion, may be likely to confound study interpretation or prevent completion of
study procedures and follow-up examinations.